Director, Kidney Cancer Center, Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard Medical School
Oncology
Dr. Toni K. Choueiri, MD
|
|
Give Review
Toni Choueiri is an expert in the field of Oncology. He attended St Joseph's University Medical School. He has 1 awards "Most Compassionate Doctor". Toni Choueiri has written publications. He has 100 publications published with PubMed. The lastest paper is: 'Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.' He accepts all Medicare patients.
Publications
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
- Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine.
- Medical androgen deprivation therapy and increased non-Cancer mortality in non-metastatic prostate Cancer patients aged â¥66 years.
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.
- Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic Renal cell carcinoma treated with vascular endothelial gro...
- Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
- Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
- Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell Renal cell carcinoma.
- ABO blood group alleles and prostate Cancer risk: Results from the breast and prostate Cancer cohort consortium (BPC3).
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
- Cancer-specific mortality of asian americans diagnosed with Cancer: a nationwide population-based assessment.
- RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy.
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized...
- HER2 as a target in invasive urothelial carcinoma.
- IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with Renal cell carcinoma.
- Kidney Cancer, version 3.2015.
- Cost implications and complications of overtreatment of low-risk prostate Cancer in the United States.
- Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma.
- RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic Renal cell carcinoma.
- Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond.
- Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-Analysis of randomized clinical trials.
- Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma.
- The somatic genomic landscape of chromophobe Renal cell carcinoma.
- PD-L1 Expression in Non-clear cell Renal Cell Carcinoma.
- Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
- Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
- The association between insurance status and prostate Cancer outcomes: implications for the Affordable Care Act.
- MET as a Target in Papillary Renal Cell Carcinoma.
- Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implicatio...
- Adrenocortical carcinoma: The management of metastatic disease.
- CytoreDuctive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Co...
- FGFR3 expression in primary and metastatic urothelial carcinoma of the Bladder.
- A phase I study of cabozantinib (XL184) in patients with renal cell Cancer.
- Overall survival in Renal-cell carcinoma with pazopanib versus sunitinib.
- Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate Cancer.
- Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-Analysis.
- Lack of reduction in racial disparities in Cancer-specific mortality over a 20-year period.
- Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer.
- Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity.
- A Systematic Review and Meta-Analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma.
- Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma.
- Kidney Cancer, version 2.2014.
- A phase 2, single-arm study of ramucirumab in patients with metastatic Renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor the...
- Optimizing bone health and minimizing skeletal morbidity in men with prostate Cancer.
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic Renal cell carcinoma.
- Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with Renal cell carcinoma receiving antiangiogenic the...
- Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
- The impact of prior platinum therapy on survival in patients with metastatic urothelial Cancer receiving vinflunine.
- The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer...
- CytoreDuctive nephrectomy in patients with metastatic non-clear cell renal cell carcinoma.
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.
- The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma.
- Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
- Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials.
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy.
- Pazopanib versus sunitinib in metastatic Renal-cell carcinoma.
- Pulmonary complications with the use of mTOR inhibitors in targeted Cancer therapy: a systematic review and meta-analysis.
- Use of Surveillance Imaging Following Treatment of Small Renal Masses.
- Metabolic complications with the use of mTOR inhibitors for Cancer therapy.
- Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate Cancer.
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective Analysis of pooled, prospec...
- Comparative effectiveness, costs and trends in treatment of small Renal masses from 2005 to 2007.
- Analgesic use and the risk of kidney Cancer: A meta-analysis of epidemiologic studies.
- Renal-cell carcinoma: a step closer to a new classification.
- Reduced penile size and treatment regret in men with recurrent prostate Cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
- Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives.
- Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-Analysis of randomized clinical ...
- Single nucleotide polymorphisms and risk of recurrence of Renal-cell carcinoma: a cohort study.
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic Renal cell carcinoma p...
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary Renal cell carcinoma.
- Risk of venous thromboembolism in patients with Cancer treated with Cisplatin: a systematic review and meta-analysis.
- Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the tre...
- BRAF mutations in metanephric adenoma of the Kidney.
- Factors Associated with the Adoption of Minimally Invasive Radical Prostatectomy in the United States.
- Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic Renal cell carcinoma: incidence, radiographic findings and correlation with clinical ou...
- Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality.
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothe...
- Association of androgen deprivation therapy with cardiovascular death in patients with prostate Cancer: a meta-analysis of randomized trials.
- Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell Cancer after sunitinib failure.
- Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
- Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer.
- Prospective evaluation of analgesic use and risk of renal cell Cancer.
- Kidney Cancer.
- VEGF inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspective.
- Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate Cancer treated with androgen-deprivation therapy.
- Incidence and Risk of Congestive Heart Failure in Patients With Renal and NonRenal Cell Carcinoma Treated With Sunitinib.
- Systemic therapy for metastatic non-clear-cell Renal cell carcinoma: recent progress and future directions.
- Renal cell carcinoma.
- Statin use and the risk of Renal cell carcinoma in 2 prospective US cohorts.
- The impact of kidney function on the outcome of metastatic Renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
- Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men with High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction.
- Progression-free survival as a predictor of overall survival in metastatic Renal cell carcinoma treated with contemporary targeted therapy.
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic Renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- AdRenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Emblem Health
- Fallon Community Health Plan
- GEHA
- Harvard Pilgrim Health Care PPO
- HealthFirst
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- Network Health
- PHP-Physicians Health Plan
- Tufts Health Plans
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Most Compassionate Doctor
Education
-
Cleveland Clinic Foundation -
St Joseph's University Medical School
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1073677209 | |
| NPPES Provider LastName | CHOUEIRI | |
| NPPES Provider FirstName | TONI | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 191.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073677209 |
| Last Name Of The Provider | CHOUEIRI |
| First Name Of The Provider | TONI |
| View All |
Similar Doctors
|
|
Dr. Inga T. Lennes, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth B. Lamont, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Yariv J. Houvras, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason E. Faris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lori J. Wirth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elgene Lim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Cleary, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salvia S. Jain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew B. Yurgelun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Hassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rameen Beroukhim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina I. Herold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Barbie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amir T. Fathi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth H. Stover, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Adam Lerner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Martell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael R. Cassidy, MD
This Doctor is OpenDoctor Recommended.
|